Skip to main content

Is the FDA's drug review process breaking down?

Since 1997 the US FDA has banned use of 11 prescription drugs because of serious side effects. The FDA says it's not the drug approval process but inappropriate prescribing that is responsible.

Written byJohn Borchardt
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

The US Food and Drug Administration (FDA) has withdrawn 11 prescription drugs from the market since 1997. Serious side effects and patient deaths have forced these withdrawals.

Is the FDA's drug review process breaking down? According to Sidney Wolfe, Director the Health Research Group (part of Ralph Nader's Public Citizen advocacy organisation), "Changes in FDA review and approval policies in the past several years appear to have led to a significant decline in the safety and efficacy standards for new drugs." Under congressional pressure the FDA has accelerated its review process. In 1997, the Congress passed the Food and Drug Administration Modernization Act expanding use of 'fast track' approval mechanisms for drugs to treat life-threatening conditions and allowing use of surrogate endpoints in clinical trials. It also included a number of mechanisms for accelerating FDA review and changed the legal standard for new drug approval to a single clinical trial ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo